NCT04613557View on ClinicalTrials.gov

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

December 21, 2022

Study Completion Date

February 28, 2037

Conditions
Relapse/Refractory Multiple Myeloma
Interventions
BIOLOGICAL

CYAD-211

Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell

DRUG

Endoxan

Preconditioning chemotherapy

DRUG

Fludara

Preconditioning chemotherapy

Trial Locations (5)

1000

Institut Jules Bordet, Brussels

2650

Universitair Ziekenhuis Antwerpen, Antwerp

8800

AZ DELTA, Roeselare

10016

Nyu Langone Hospitals, New York

33612

H. Lee Moffitt Cancer Center, Tampa

Sponsors

Lead Sponsor

Celyad Oncology SA
All Listed Sponsors
lead

Celyad Oncology SA

INDUSTRY

NCT04613557 - Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter